Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 660
Views PDF (Tiếng Việt): 614
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1258
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Trang, M. T. ., Tiệp, N. K. ., & Nhung, P. H. . (2023). 2. The minimum inhibitory concentration of vancomycin and the antibiotic persistence character to vancomycin of Staphylococcus aureus. Journal of Medical Research, 160(12V2), 12-18. https://doi.org/10.52852/tcncyh.v160i12V2.1258

2. The minimum inhibitory concentration of vancomycin and the antibiotic persistence character to vancomycin of Staphylococcus aureus

Mai Thi Trang, Nguyen Khac Tiep, Pham Hong Nhung

Main Article Content

Abstract

This study assessed the minimum inhibitory concentration (MIC) of vancomycin in inhibiting the growth of Staphylococcus aureus (S. aureus) and its antibiotic persistence character. A total of 213 Staphylococcus aureus strains were isolated from blood or catheter specimen by the Microbiology Department of Bach Mai Hospital from 02/2022 to 08/ 2022. Vancomycin’s MIC was determined using the broth microdilution method. The result shows that the frequency of MRSA was 61.4%. Vancomycin’s MIC ranged from 0.25 µg/ml to 1 µg/ml, and 128 strains (60.1%) had MIC of vancomycin of 1 µg/ml. There was no case of resistance to vancomycin. After performing antibiotic persistence test of 52 randomly-chosen strains, high persister frequency was observed in all of them. There was no significant differences in persistence frequency when comparing S. aureus strains with MIC of 0.5 µg/ml and strains with MIC of 1 µg/ml.

Article Details

Keywords

Staphylococcus aureus, MIC, persistence antibiotic, vancomycin

References

1. Chambers S. Diagnosis and management of staphylococcal infections of vascular grafts and stents. Intern Med J. 2005;35(s2):S72-S78. doi: 10.1111/j.1444-0903.2005.00981.x.
2. Lê Huy Thạch, Lê Văn Thanh, Đỗ Thuỳ Dung. Nồng độ ức chế tối thiểu (MIC50 và MIC90) của vancomycin đối với các chủng staphylococcus aureus kháng methicillin (MRSA) tại Bệnh viện Ninh Thuận 2017. Thời sự Y học. 2017;12:47-50. http://hoiyhoctphcm.org.vn/wp-content/uploads/2018/06/09F-Le-H-Thach-MIC-vanco-NiThuan-4tr47-50.pdf.
3. Bộ Y tế, GARP-Việt Nam, Đơn vị Nghiên cứu Lâm sàng ĐH Oxford. Báo cáo sử dụng kháng sinh và kháng kháng sinh tại 15 bệnh viện Việt Nam năm 2008 - 2009. Accessed June 15, 2021. http://benhnhietdoi.vn/UploadFiles/2018/12/20/Bao_cao_su_dung_khang_sinh_va_khang_khang_sinh_tai_15_benh_vien_nam_2008-2009.pdf.
4. Foucault ML, Courvalin P, Grillot-Courvalin C. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(6):2354-2359. doi: 10.1128/AAC.01702-08.
5. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol. 2008;57(Pt 1):72-79. doi: 10.1099/jmm.0.47144-0.
6. Périchon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(11):4580-4587. doi: 10.1128/AAC.00346-09.
7. Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect. 2008;57(2):110-115. doi: 10.1016/j.jinf.2008.04.003.
8. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus biofilms. Virulence. 2011;2(5):445-459. doi: 10.4161/viru.2.5.17724.
9. Jones SM, Morgan M, Humphrey TJ, Lappin-Scott H. Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms. Lancet Lond Engl. 2001;357(9249):40-41. doi: 10.1016/S0140-6736(00)03572-8.
10. Balaban NQ, Helaine S, Lewis K, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441-448. doi: 10.1038/s41579-019-0196-3.
11. Tiệp NK, Xuân ĐT, Anh LTT, et al. Dai dẳng kháng sinh - một kiểu hình liên quan đến giảm hiệu quả điều trị nhiễm khuẩn trên lâm sàng cần được quan tâm. Published online 2021:7.
12. Nguyen TK, Peyrusson F, Dodémont M, et al. The persister character of clinical isolates of Staphylococcus aureus contributes to faster evolution to resistance and higher survival in THP-1 monocytes: A study with moxifloxacin. Front Microbiol. 2020;11:587364. doi: 10.3389/fmicb.2020.587364.
13. CLSI-M100. Performance Standards for Antimicrobial Susceptibility Testing. 30th edition. Published Jan 2020.
14. CLSI-M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Published Jan 2015. pdf.
15. Holmes NE. Using AUC/MIC to guide vancomycin dosing: Ready for prime time?. Clin Microbiol Infect. 2020;26(4):406-408. doi: 10.1016/j.cmi.2019.12.023.
16. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1):82-98. doi: 10.2146/ajhp080434.